Loading color scheme
Scioto Biosciences is advancing a proprietary Activated Bacterial Therapeutics (ABT) platform for delivering best-in-class, live therapeutic bacteria to the gut. Scioto’s lead candidate, SB-121, has the potential to reduce disease burden in any disorder associated with a “leaky gut,” including clostridium difficile infections, irritable bowel syndrome, diabetes, oncology and various other chronic diseases.
Earlier this month, Scioto Biosciences, Inc. began their Phase Ib clinical trial of SB-121 for the treatment of Autistic DIsorder (AD).
Read moreScioto Biosciences announced today the closing of a strategic investment of up to $26.5M from Genome & Company and other investors to join in an upcoming tranche. Genome & Company is a leading microbiome company with headquarters in South Korea. The deal gives Genome & Co a majority stake in Scioto and expands its presence into the US.
Read moreScioto Biosciences, a preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, today announced that they are a recipient of a Phase II SBIR grant from the National Institutes of Health (NIH) for $2.3 million.
Read moreScioto Biosciences, a preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, today announced it has closed on $1.8M in Series A financing to support the launch of its new microbiome platform technology.
Read more